A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate Helicobacter pylori infection; A pilot study for the large Linqu County trial

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 5, 2010, Pages 597-601

  Ma, Junling ^a   Liu, Weidong ^b   Zhang, Lian ^a   Pan, Kaifeng ^a   Zhao, Hongjun ^b   Zhou, Tong ^a   Winawer, Sidney ^c   Zauber, Ann ^c   Classen, Meinhard ^d   You, Weicheng ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b Linqu Public Health Bureau   (China)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

10 day quadruple therapy; H. pylori infection; Population based study

Indexed keywords

BISMUTH CITRATE; METRONIDAZOLE; OMEPRAZOLE; PLACEBO; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BLOATING; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ERADICATION THERAPY; FATIGUE; FEMALE; HELICOBACTER INFECTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELENA; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; STOMACH CANCER; TREATMENT OUTCOME; UREA BREATH TEST;

ADULT; ANTACIDS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; BISMUTH; BREATH TESTS; CARBON ISOTOPES; CHINA; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PATIENT COMPLIANCE; PILOT PROJECTS; PLACEBOS; RURAL POPULATION; TETRACYCLINE; UREA;

EID: 77951264440     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283337146     Document Type: Article

References (23)

1. IARC Working Group on the, Evaluation of Carcinogenic, Risks to Humans. Lyon, 7-14 June 1994. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61:177-240.
2. Tally NJ. Is it time to screen and treat H pylori to prevent gastric cancer (Comment). Lancet 2008; 372:350-352.
3. Zhang L, Blot WJ, You WC, Chang YS, Kneller RW, Jin ML, et al. Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 1996; 5:627-630.
4. You WC, Zhang L, Pan KF, Jiang J, Chang YS, Perez-perez GI, et al. Helicobacter pylori prevalence and CagA status among children in two counties of China with high and low risks of gastric cancer. Ann Epidemiol 2001; 11:543-546.
5. You WC, Zhang L, Gail MH, Chang YS, Liu WD, Ma JL, et al. Gastric dysplasia and gastric cancer: H. pylori, serum vitamin C and other risk factors. J Natl Cancer Inst 2000; 92:1607-1612.
6. You WC, Brown L, Zhang L, Li JY, Jin ML, Chang YS, et al. Randomized double-blind factorial trial of three treatments to reduce prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98:974-983.
7. Wang WH, Wong BC, Lam SK. Helicobacter pylori infection, pooled analysis of Helicobacter pylori eradication regimes in Asia. J Gastroenterol Hepatol 2000; 15:1007-1017.
8. Zhang L, Shen L, Ma JL, Pan KF, Liu WD, Li J, et al. Eradication of Helicobacter pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy. World J Gastroenterol 2006; 12:3915-3918. (Pubitemid 44028409)
9. Gisbert JP, Gonzá lez L, Calvet X, Roqué M, Gabriel R, Pajares JM. Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week - a meta-analysis of efficacy. Aliment Pharmacol Ther 2000; 14:1141-1150.
10. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16:167-180.
11. O'Morain C, Borody T, Farley A, De Boer WA, Dallaire C, Schuman R, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 2003; 17:415-420.
12. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spé nard J. Bismuthbased quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98:562-567.
13. Zheng Q, Dai J, Li X, Lu H, Xiao S. Comparison of the efficacy of pantoprazole-based triple therapy versus quadruple therapy in the treatment of Helicobacter pylori infection. Chines J Gastroenterol 2009;14:38-40.
14. You WC, Zhang L, Gail MH, Ma JL, Chang YS, Blot WJ, et al. Helicobacter pylori infection, garlic intake and precancerous lesions in a Chinese population at low risk of gastric cancer. Int J Epidemiol 1998; 27:941-944.
15. Klein PD, Malaty HM, Martin RF, Graham KS, Genta RM, Graham DY. Noninvasive detection of Helicobacter pylori infection in clinical practice: the 13C-urea breath test. Am J Gastroenterol 1996; 91:690-694.
16. Jiang J, Wang SZ, Li XM, Jiang GH, Chen SP, Bei L. The modification of 13C-urea breath test. Zhonghuaheyixuezaizhi 1994; 14:103-105.
17. De Boer WA. Bismuth based triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999; 11:697-700.
18. De BoerWA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol 1996; 22:313-316.
19. Van Doorn LJ, Figueiredo C, Mégraud F, Pena S, Midolo P, Queiroz DM, et al. Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology 1999; 116:823-830.
20. De Boer WA, Tytgat GNJ. Should anti-Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis? Eur J Gastroenterol Hepatol 2001; 13:1281-1284.
21. Fulian Hu. Antibiotic resistance status of H. pylori in China. Chin J Gastroenterol Hepatol 2008; 17:517-518.
22. Gisbert JP, Pajares JM. Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16:1047-1057.
23. Pan K, Zhang L, Jiang J, Ma J, Zhou T, Guan W, et al. The prevalence of Helicobacter pylori and cagA+ infection in children at high and low risk of gastric cancer. Chin J Prev Med 1999; 33 (Suppl):38-40.